Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02235272 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation
A Phase 3 study of Pain and Inflammation, sponsored by Xigen.
- Completed
- Registry status
- Phase 3
- Development phase
- 339
- Enrollment target
- 1
- Study location
NCT02235272: Completed Phase 3 study of Pain and Inflammation, sponsored by Xigen.
NCT02235272 is a Phase 3 study of Pain and Inflammation that has completed, run by Xigen. The registered enrollment target is 339 participants, above the 303-participant average among 374 other Pain trials with a reported enrollment target (12% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02235272, a Phase 3 study of Pain and Inflammation, has completed, sponsored by Xigen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 339 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the clinical efficacy and safety of XG-102 (900µg) compared to vehicle in the treatment of subjects with inflammation and pain following cataract surgery.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG XG-102
Study Locations (1)
California
- - Garden Grove
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 339 participants |
| Start Date | 2014-09 |
| Est. Completion | 2015-12 |
| Phase | Phase 3 |
What the finished NCT02235272 record still lists
NCT02235272 is an interventional study that assigns participants to a tested intervention. The registered 339 participants enrollment target is mid-sized for trials with a published cap, above the 303-participant average among 374 other Pain trials with a reported enrollment target (12% higher).
The record links to 3 conditions, with Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02235272 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02235272 about?
NCT02235272 is a clinical study titled "Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation". The purpose of this study is to evaluate the clinical efficacy and safety of XG-102 (900µg) compared to vehicle in the treatment of subjects with inflammation and pain following cataract surgery.
What is the current status of trial NCT02235272?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 339 participants. The study started on 2014-09. Estimated completion is 2015-12.
What conditions does trial NCT02235272 study?
This clinical trial studies the following conditions: Pain, Inflammation, Cataract.
What interventions are being tested in trial NCT02235272?
The interventions under investigation include: Placebo (DRUG), XG-102 (DRUG).
Who is sponsoring clinical trial NCT02235272?
This trial is sponsored by Xigen, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02235272 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02235272's enrollment target sits among peer trials
339 55th of 374 higher than 320 of 374 other Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of NSAIDs on Union, Opioid Utilization and Pain Management for Tibia Fractures: A Pragmatic, Randomized Controlled Trial
RECRUITING · Phase 3
-
Opioid-Free Orthopaedics
RECRUITING · Phase 3
-
Suzetrigine in Total Hip Arthroplasty
RECRUITING · Phase 3
-
Optimizing Chronic Pain Care With Mindfulness and Chronic Pain Management Visits
RECRUITING · Phase 3
-
Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment
RECRUITING · Phase 3
-
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04176172 · 340 participants · Phase 3
Optimizing Tobacco Use Treatment for PLWHA
- NCT04545424 · 340 participants · Phase 2
Trial of Therapeutic Hypothermia in Patients With ARDS
- NCT04806958 · 340 participants · NA
The PulsePoint Study
- NCT05323409 · 340 participants · NA
Improving Comprehensive Care of Cancer Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia